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Elective Neck Dissection Versus Observation in Patients With
Head and Neck Cutaneous Squamous Cell Carcinoma
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BACKGROUND: The survival benefit of elective neck dissection (END) for patients with cutaneous squamous cell carcinoma (cSCC) of
the head and neck and no evidence of regional metastasis (cN0) has never been reported. The aim of this study was to determine the
effect of END on patient survival. METHODS: The authors included patients with head and neck cSCC who had undergone primary surgery from 1995 to 2017. The primary end point was survival, and the secondary end points were the incidence of occult regional disease
and regional disease control. To assess the impact of END on survival, the authors used multivariable Cox proportional hazards models
with propensity score and matching techniques for internal validation. RESULTS: A total of 1111 patients presented with no evidence of
nodal disease; 173 had END, and 938 were observed. Adjuvant radiotherapy to the neck was administered to 101 patients (9%). END
resulted in a 5-year overall survival rate of 52%, whereas the rate was 63% in the observation group (P = .003 [log-rank]). The 5-year
disease-free survival rate for patients undergoing END was similar to that for the observation group (73% vs 75%; P = .429). A multivariate regression model showed that the performance of END was not associated with improved rates of overall, disease-specific, or
disease-free survival; similarly, among patients with advanced disease (T3-4), those who underwent END did not have improved survival
rates. CONCLUSIONS: Among patients with cSCC of the head and neck, observation of the neck nodes resulted in noninferior survival
rates in comparison with END at the time of primary surgery. Further studies are required to elucidate the role of END in patients with
advanced disease. Cancer 2021;0:1-8. © 2021 American Cancer Society.
KEYWORDS: head and neck, lymph node, metastasis, neck dissection, skin, squamous cell carcinoma, survival.

INTRODUCTION
Cutaneous squamous cell carcinoma (cSCC) most commonly occurs in the head and neck region.1 The majority of newly
diagnosed cSCCs are early-stage tumors that can be successfully cured with surgical excision.2 However, a subset of cSCCs is
associated with high-risk features such as poor histologic differentiation; greater depth of invasion (≥2 mm); perineural, vascular, or lymphatic invasion; and patient immunosuppression. These high-risk cSCCs carry an increased risk for local recurrence
and regional metastasis.2-6 Although the management of regional cSCC metastases to the parotid gland and neck with therapeutic nodal dissection and optional adjuvant radiotherapy—and, in selective cases, chemoradiotherapy—is widely accepted,
the optimal management of high-risk, node-negative head and neck cSCC remains controversial.7,8 Depending on their age,
morbidity, and clinical and pathologic risk factors, these patients may be managed by either a wait-and-see approach (observation) or elective neck dissection (END).7 Furthermore, the impact of occult nodal metastasis on survival in cSCC remains
to be established.9 In this study, we wanted to determine the effect of END on patient survival in clinically node-negative
head and neck cSCC. Secondary aims were to determine the incidence of occult regional disease and regional disease control.
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MATERIALS AND METHODS

Statistical Analysis

Patients

We used the Kaplan-Meier method to calculate the rates
of overall survival (OS; the time elapsed from the date
of surgery to the date of death or censoring at last follow-up), disease-specific survival (DSS; the time elapsed
from the date of diagnosis to death resulting from cSCC),
disease-free survival (the time elapsed from the date of
surgery to the first signs or symptoms of cSCC recurrence), and regional control (the time elapsed from the
date of surgery to the first signs or symptoms of cSCC
nodal recurrence). The log-rank test was used to assess
the differences in survival and control rates.14,15 The Cox
proportional hazards regression model was used to compare the factors with prognostic potential.16 We applied
a process of several steps to develop a final model. The
first step was to study the correlation between DSS or
OS and each covariable via a univariable Cox proportional hazards regression model and then a preliminary
multivariable Cox proportional hazards regression model.
Thus, covariates with a univariable P value < .2 were included in the preliminary multivariable model. Variables
that remained statistically significant (P < .05) were included in the final multivariable model. A 2-step matching process was implemented. First, all eligible controls
were matched according to their age, sex, and T classification. In the second step, we applied 1:1 propensity score
matching with the Mahalanobis distance. The variables
included in the propensity score matching were age, sex,
ethnicity, recurrence status on presentation, immunosuppression status, and T classification. P < .05 was defined
as significant, and 2-sided statistical tests were used in all
calculations using JMP (version 14; SAS Institute, Inc,
Cary, North Carolina). The study was approved by the
institutional review board committees of MD Anderson
Cancer Center.

On June 16, 2020, we searched the REDCap cSCC registry in the Department of Head and Neck Surgery of
The University of Texas MD Anderson Cancer Center for
patients with head and neck cSCC who had undergone
primary surgery at our institution from 1995 to 2017.
Inclusion criteria included no evidence of regional metastasis (cN0) on physical examination reports or imaging studies (ie, ultrasonography, computed tomography,
positron emission tomography–computed tomography,
or magnetic resonance imaging).10 Patients with less than
6 months of follow-up were excluded unless an event (ie,
disease-specific death or recurrence) was recorded within
6 months of surgery. Patients with prior neck regional dissection or radiotherapy were excluded. Staging was determined by physical examination, computed tomography,
ultrasonography, magnetic resonance imaging, and/or
positron emission tomography–computed tomography.
All staging was completed according to the guidelines of
the American Joint Committee on Cancer (8th edition).11
All cases were presented at a multidisciplinary conference.
Adjuvant radiotherapy with or without concurrent systemic therapy was administered to patients with T3-4 or
N2-3 tumors, extranodal extension, involved margins,
or perineural invasion. Indications for END were tumor
extension to high-risk regions according to the National
Comprehensive Cancer Network guidelines for cSCC
(ie, central face, lips, preauricular and postauricular skin,
temple, and ears), the presence of perineural or lymphovascular invasion on presurgical biopsy, and recurrence
on presentation that required free flap reconstruction.12
Univariate analysis followed by multivariate logistic regression analysis of patients undergoing END versus
observation was used to confirm that in our cohort, a
high-risk site (P = .012) and recurrence on presentation
(P = .034) were significant determinants of neck management (Supporting Table 1). Observed cases were monitored with physical examination and neck computed
tomography or ultrasonography every 1 to 3 months for
year 1, every 2 to 4 months for year 2, and every 4 to
6 months for years 3 to 5.
Histopathologic Analysis

Both primary and neck dissection specimens underwent
a standard pathologic evaluation by a certified dermatopathologist or head and neck pathologist. Specimens were
dissected and tissues were sampled as recommended by
the guidelines for the histopathologic evaluation of head
and neck carcinoma.13
2

RESULTS
A total of 1582 patients were surgically treated consecutively for head and neck cSCC at our institution during
the study period; 1111 of those patients presented with
no evidence of nodal disease and were eligible for study
inclusion (Fig. 1). One hundred seventy-three patients
(16%) underwent END; 131 of these (12%) involved
parotidectomy. The remaining 938 patients (84%) were
managed with observation followed by therapeutic neck
dissection at the time of regional recurrence.
Patients’ demographic and clinical characteristics are
summarized in Table 1. Of the 1111 patients included in
this study, 952 (86%) were male, and 159 (14%) were
female; the median age was 70 years (range, 19-97 years).
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Figure 1. Patient population and Kaplan-Meier analysis. (A) Consolidated Standards of Reporting Trials flowchart of the study
population. (B) Five-year OS and (C) DSS calculated by the Kaplan-Meier method according to the neck management status. cSCC
indicates cutaneous squamous cell carcinoma; DSS, disease-specific survival; END, elective neck dissection; OS, overall survival.

The distribution of the patients according to ethnicity
was as follows: White, 1055 (95%); Asian, 34 (3%); and
Hispanic, African American, or other, 22 (2%). Chronic
immunosuppression was present in 256 patients (23%),
hematologic malignancies (eg, chronic lymphocytic leukemia) were present in 86 (8%), and organ transplantation was performed in 38 patients (3%).
Advanced disease (T3-4) was more common in the
patients who underwent END (58% vs 25%; P < .001).
Fifty-four patients (31%) in the END group received adjuvant therapeutic-dose irradiation to the lateral neck fields,
whereas 47 (5%) did in the no-END group (P < .001).
Total radiation doses ranged from 50 to 70 Gy, with no difference in the mean doses (52 ± 1.24 and 52 ± 1.33 Gy in
the END and no-END groups, respectively; P = .798).
The 5-year OS rate was 52% for patients who underwent END and 63% for patients who did not (P = .003
[log-rank]; Fig. 1). The 5-year DSS rate was 74% for
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patients who underwent END and 89% for patients who
did not (P < .001 [log-rank]; n = 1001 [the cause of
death was not available for 110 patients]). At 5 years, the
disease-free survival rates were similar in the END and
observation groups (73% vs 75%; P = .429).
Throughout the study period, there were 34 recurrences (14 of which were regional) and 97 deaths in the
END group and 155 recurrences (49 of which were regional) and 282 deaths in the observation group. The 5-
year regional recurrence rates did not differ between patients
who underwent END (8%) and those who did not (5%;
P = .138; Fig. 2). Notably, 41 of the 49 patients (84%) who
developed regional recurrence after observation were treated
with therapeutic neck dissection for their relapse; only 6 patients with regional recurrence treated with therapeutic neck
dissection died of head and neck cSCC.
The overall rate of occult nodal metastasis among
patients who underwent END was 21% (36 of 173). A
3
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TABLE 1. Patient Demographic and Clinical Characteristics
Variable

Elective Neck Dissection

No Neck Dissection

173 (16)
90 (52)
69 ± 11

938 (84)
257 (27)
70 ± 12

152 (88)
21 (12)

800 (85)
138 (15)

134 (77)
21 (12)
4 (2)
8 (5)
4 (2)
1 (<1)
0 (0)
4 (2)

714 (77)
74 (8)
82 (9)
39 (3)
20 (2)
15 (2)
3 (<1)
19 (2)

36 (21)
37 (21)
75 (43)
25 (15)

607 (65)
101 (11)
183 (19)
47 (5)
N/A

No. of patients (%)
Recurrence on presentation, No. (%)
Age, mean ± SD, y
Sex, No. (%)
Male
Female
Immunosuppression, No. (%)
None
IDDM
Hem/Onc
Organ transplant
Steroid use
AID
HIV/AIDS
Other
Pathologic T classification, No. (%)
T1
T2
T3
T4
Pathologic N classification, No. (%)
N0
N1
N2
N3
Lateral neck irradiation: yes, No. (%)
Adjuvant chemotherapy: yes, No. (%)
Follow-up, median (range), mo

P
<.001
.732
.365

.826

137 (79)
17 (10)
9 (5)
10 (6)
54 (31)
36 (21)
26 (6-217)

<.001

<.001
<.001
.7518

47 (5)
34 (4)
24 (2-254)

Abbreviations: AID, autoimmune disease; Hem/Onc, hematologic/oncologic; IDDM, insulin-dependent diabetes mellitus; N/A, not applicable.
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Figure 2. Kaplan-Meier analysis. (A) Five-year RR and (B) DFS calculated by the Kaplan-Meier method according to the neck
management status. DFS indicates disease-free survival; RR, regional recurrence.

subgroup analysis of OS and DSS rates by nodal status
in patients who underwent END revealed no differences
between patients with and without occult metastases
(Supporting Fig. 1). Because many more patients underwent observation (84%) rather than END, to control for
a potential selection bias, we matched 298 patients (149
per group) for age, sex, ethnicity, recurrence status on
presentation, immunosuppression status, and T classification. This internal validation method was chosen over
others because matching techniques have been shown to
produce stable and nearly unbiased estimates of predictive
4

accuracy with increased power and decreased variability,
regardless of the sample size. As shown in Supporting
Figure 2, there were no differences in OS (P = .754 [log-
rank]) or DSS (P = .192 [log-rank]) between the matched
groups.
The 5-year OS rate was 44% for patients with locally advanced disease (T3-4) who underwent END and
54% for those who did not undergo END (P = .070 [log-
rank]; Fig. 3); among patients with T1-2 tumors, the 5-
year OS rate was 61% for those who had END and 66%
for those who did not (P = .431 [log-rank]). Interestingly,
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Figure 3. Kaplan-Meier analysis. Five-year OS of patients with (A) early (T1-2) and (C) advanced (T3-4) head and neck cutaneous
squamous cell carcinoma and 5-year DSS of patients with (B) early (T1-2) and (D) advanced (T3-4) head and neck cutaneous
squamous cell carcinoma calculated by the Kaplan-
Meier method according to the neck management status. AJCC indicates
American Joint Committee on Cancer; DSS, disease-specific survival; OS, overall survival.

patients with early disease (T1-2) who did not have END
had better 5-year DSS rates than those who had END
(94% vs 78%; P < .001 [log-rank]). Among patients with
locally advanced disease (T3-4), we found no difference
in DSS (P = .428).
The variables that were introduced into the Cox
regression model (n = 1111) were age, sex, immunosuppression status, recurrence status at presentation,
margin status, T and N classification, presence/absence
of neural invasion, treatment group (surgery, surgery
and radiotherapy, or surgery and chemoradiation), and
neck management (END vs observation). In the multivariate analysis, age, immunosuppression status, and
presence/absence of neural invasion, but not neck management, were independently associated with both OS
and DSS (Table 2).
DISCUSSION
Most cSCCs present at an early stage, and data on the
impact of nodal metastases on cSCC outcomes are
scarce and insufficient to determine the optimal role
of elective neck treatment. In mucosal head and neck
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squamous cell carcinoma (SCC), an END is generally
indicated if the probability of occult cervical metastases
is greater than 15% to 20%.17 Our finding of a 20%
rate of occult neck metastases in patients with cSCC
would seem to support the performance of END in patients with cSCC as practiced in those with mucosal
SCC. However, our data indicate a lack of a survival advantage in patients who had END compared with those
who were observed. The low rate of regional recurrence
in patients who were observed (49 of 938 [5%]) makes
the overall occult incidence rate for this study much
lower than the conventional threshold for END. This
might explain the favorable neck control rates in our
study and should be taken into consideration when one
is contemplating management of the neck in cSCC.
Furthermore, our subgroup analyses suggest that END
did not improve survival rates, even for patients with
advanced disease (T3-4). Interestingly, the regional recurrence rate in the observation group was lower than
the rate of occult nodal metastasis in the END group.
This patient population is generally older, and it is possible that patients with occult nodal metastasis are lost
5
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TABLE 2. Cox Regression Analysis of Prognostic Factors for Overall and Disease-Specific Survival
Overall Survival
Variable
Age
Sex
Recurrence on presentation
Chronic immunodeficiency
Pathologic T classification

Pathologic N classification

Margin status
Neural invasion
Radiotherapy
Chemotherapy
Elective neck dissection

y
Male
Female
No
Yes
No
Yes
T1
T2
T3
T4
N0
N1
N2
N3
Negative
Positive
No
Yes
No
Yes
No
Yes
No
Yes

Disease-Specific Survival

Regional Recurrence–Free
Survival

P

HR

95% CI

P

HR

95% CI

<.001
.039

1.049
1
0.647
1
1.179
1
1.802
1
1.492
1.240
1.995
1
0.661
1.018
1.787
1
0.783
1
1.770
1
0.593
1
1.155
1
1.364

3.60-6.26

<.001
.415

1.024-1.060

.917

1.042
1
0.805
1
1.090
1
1.879
1
1.298
1.537
1.184
1
1.298
1.537
1.183
0.977

0.706-2.388
0.748-3.157
0.527-2.660
0.636-1.502

.419

.028

1.951

1.037-3.673

<.001

.084

0.668

0.424-1.053

.180

.522

1
1.238
1
1.169

.238
<.001
.024

.3773

.162
.033
.004
.597
.080

0.428-0.977
.654
0.896-1.551
.003
1.332-2.442
.311
1.014-2.196
0.737-2.088
1.142-3.484
.778
0.276-1.581
0.354-2.931
0.801-3.985

P
.093
.488

0.471-1.374
.848
0.748-1.588
.182
1.266-2.788
.013
0.706-2.387
0.748-3.157
0.527-2.660
.119

HR

95% CI

1.026
1
0.704
1
1.071
1
1.638
1
1.057
0.051
0.022
1
2.134
5.976
4.278
1.412

0.996-1.058
0.262-1.893
0.528-2.174
0.793-3.382
0.374-2.987
0.008-0.350
0.002-0.256
0.407-11.202
1.381-25.848
N/A
0.611-3.267

0.557-1.103
1.043-2.674
0.145-0.846
0.676-1.974
.527
0.963-1.931

.024
0.652-2.351
.995
0.724-1.888

1
37.392
1
0.549
1
3.244
1
0.997

5.059-276.399
0.228-1.317
1.166-9.032
0.380-2.615

Abbreviations: CI, confidence interval; HR, hazard ratio; N/A, not applicable.

to follow-
up because of a non–
cancer-
related death
before the clinical presentation of regional recurrence.
Although this might suggest a selection bias associated
with the decision of whether to perform END, it also
highlights the potentially modest impact that END has
in this patient population. This should be further evaluated prospectively. Still, regardless of the patient characteristics or clinical reasons that led to the performance
of END, regional recurrence was not different between
the END and observation groups, and most patients in
the observation group who had a regional recurrence
were successfully treated with salvage therapeutic neck
dissection.
The less prominent survival advantage of END in
cSCC versus mucosal SCC may be due to the older age
of cSCC patients (median age, 70 vs 55 years) and the
higher rates of immunosuppressive comorbidities (eg,
insulin-
dependent diabetes mellitus and hematologic
malignancies). This is further demonstrated by the relatively low rate of cancer-related death after 5 years among
patients who did not have END (11%) in comparison
with the overall death rate (37%). Also, our multivariate
regression analysis identified only age, immunosuppression status, and the presence/absence of neural invasion,
rather than the systemic treatment regimen (ie, adjuvant
6

chemotherapy), as independent determinants of both OS
and DSS. This is consistent with our hypothesis that patient factors, rather that tumor pathologic features (especially nodal metastasis), are associated with survival, and
it is supported by previous data also showing that immunosuppression is a predictor of both outcomes and rates
of nodal metastasis in cSCC.18,19
This study has several limitations. Treatment was
not assigned in a randomized fashion; this might suggest
underlying issues that resulted in worse prognoses for patients who had END. That said, our multivariate analysis
revealed that adjuvant radiotherapy was associated with a
significantly lower risk of death of any cause (P = .004)
and a marginally significantly lower risk of cancer-specific
death (P = .08). These findings, together with previous
reports with a higher rate of occult regional metastasis
and the potential survival benefit with neck radiation
in patients with cSCC, suggest that adjuvant radiation
might be beneficial and should be considered in these
patients.20,21
Although it is not possible to disentangle these patient factors from the “direct” effect of END, our propensity score–
based matching validation showed no
survival benefit for patients who had END, even among
patients with advanced disease. Although our finding of
Cancer  

Month 0, 2021

END in Head and Neck Skin SCC/Amit et al

significantly higher DSS rates in patients with early disease (T1-2) who did not have END in comparison with
those who had END suggests that deaths in this patient
population might be related to preexisting or procedure-
associated morbidities, the study design precluded us from
concluding that. We found higher rates of advanced and
recurrent disease in the END group, yet our multivariate
regression analysis did not identify these factors as potential causes of the difference in survival rates. The study
spans over 25 years, and although treatment trends have
changed during this period of time, we present a standardized approach practiced by our multidisciplinary team.
Furthermore, no evidence of heterogeneity between time
periods (1995-2009 and 2010-2019) was noted. It is important to note that most patients were closely monitored
for regional recurrence by physical examination and ultrasonography or computed tomography in the first 2 years
after their surgery. Hence, the feasibility of neck surveillance and salvage surgery in case of recurrence should be
considered when one is deciding whether or not to perform an END. Taken together, these findings support further evaluation of less extensive surgical approaches (eg,
sentinel lymph node biopsy for high-risk T1 patients or
any T2 patient) or observation of the regional lymphatics
in patients who are clinically node negative, even those
with advanced or recurrent disease at the primary site.
Although this was a large study and there was internal validation by matching, a prospective clinical trial is needed
to fully assess the role of END in cSCC. Until then, the
regional treatment of patients with cSCC should be based
on risk stratification and multidisciplinary input.
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